Press Releases Camurus AB

Equities

CAMX

SE0007692850

Real-time Estimate Cboe Europe Other stock markets 05:41:09 2024-06-07 am EDT			5-day change	1st Jan Change
593.5 ^SEK	+0.59%		+2.07%	+10.22%

May. 23	Camurus' Rare Growth Disorder Drug Accepted for Review in EU	MT
May. 23	Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2024/2027	May. 30	AQ
Camurus to present at Jefferies 2024 Healthcare Conference New York	May. 28	AQ
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly	May. 23	AQ
Camurus : AGM minutes 2024	May. 13	PU
Resolutions at the annual general meeting 2024 in Camurus	May. 08	AQ
Camurus' Interim Report January-March 2024	May. 08	AQ
Notice of annual general meeting 2024 in Camurus (publ)	Apr. 02	AQ
Camurus Annual Report for 2023	Mar. 28	AQ
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	Mar. 05	AQ
Camurus' Full Year Report 2023	Feb. 15	AQ
Camurus appoints Behshad Sheldon as President of Camurus Inc.	Feb. 13	AQ
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease	Feb. 08	AQ
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million	Jan. 17	AQ
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023	Jan. 17	AQ
Change in number of shares and votes in Camurus	Dec. 29	AQ
Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly	Dec. 21	AQ
Camurus to enter Large Cap segment on Nasdaq Stockholm	Dec. 20	AQ
Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors	Dec. 14	AQ
Camurus' Interim Report Third Quarter 2023	Nov. 09	AQ
Camurus : receives improved ESG risk rating by Sustainalytics	Nov. 05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Camurus AB

Equities

CAMX

SE0007692850

Press Releases

Filters